At three years, 69% of patients treated with Imfinzi and chemotherapy around surgery were alive, compared with 62% of patients treated with chemotherapy alone.
|Articles|April 15, 2016
- Gastrointestinal Special Issue
- Volume 1
- Issue 1
Medical Illustration: Targeting HER2 in Gastric Cancer
Author(s)Erin Moore
For about 20 percent of patients with advanced gastric cancer, tumors overproduce a receptor protein called HER2.
Advertisement
ILLUSTRATION BY ERIN MOORE
ORIGINALLY PUBLISHED IN “GUT REACTION,” CURE WINTER 2009
*HER2 is also associated with breast cancer.
For about 20 percent of patients with advanced gastric cancer, tumors overproduce a receptor protein called HER2.
Articles in this issue
over 10 years ago
In Gastroesophageal Cancers, Better Prevention and Treatments Neededover 10 years ago
An Insight Into Gastric Cancers and Life Without a Stomachover 10 years ago
Changing Lives With ImmunotherapyAdvertisement
Related to this article
Advertisement
Advertisement